Home
Parallel Trade

SAE Media Group presents Europe's leading 14th annual Parallel Trade conference, taking place in London on the 4th-5th of February 2020. As the only  B2B parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The size of the EU market in pharmaceutical distribution is around €5bn, and the UK accounts for 22.7% of this figure. The sector has an annual import value of around £1bn, while the annual export figure approximates £600m.

The 2020 event will hold a particular place of significance on shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights.

Furthermore, this conference will give companies affected the perfect opportunity to discuss and consider the impact of the FMD (Falsified Medicines Directive) implementation on their practices and on the market.

 


 

FEATURED SPEAKERS

Christopher Stothers

Christopher Stothers

Partner, Freshfields Bruckhaus Deringer LLP
David Guest

David Guest

Manager, Parallel Import Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
Dermot Glynn

Dermot Glynn

Senior Advisor, Europe Economics
Farasat Bokhari

Farasat Bokhari

Associate Professor, UEA, University of East Anglia
Jeremy Blum

Jeremy Blum

Partner, Bristows
John Lisman

John Lisman

Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
Martin Slegl

Martin Slegl

Regional Principal of East Europe, IQVIA
Peter Bogaert

Peter Bogaert

Managing Partner, Covington & Burling
Shabnam Hanassab

Shabnam Hanassab

Engagement Manager, IQVIA
Werner Berg

Werner Berg

Partner, Baker & Mckenzie
Wesley Lepla

Wesley Lepla

Regulatory Lawyer, Covington & Burling

Aqeel Kadri

Senior Associate , White & Case LLP
Aqeel Kadri

Aqeel Kadri’s practice spans public and private enforcement of competition law. He has litigated a range of competition law and State aid cases before the European and English Courts, as well as acting for and advising clients in relation to investigations by the European Commission and CMA. He regularly advises large pharmaceutical companies on a range of competition law issues, notably pricing of dominant products and investigations by competition authorities into pricing practices.

Beatriz San Martin

Partner, Arnold & Porter
Beatriz San Martin

Beatriz has significant intellectual property experience handling cases before the UK Courts and the CJEU, including high-profile European litigation. In addition to her patent and SPC experience, she also counsels on and litigates other IP rights including copyright, trademark, passing off, design rights, database rights and confidential information. Her cases have involved a wide range of technologies including pharmaceuticals, medical devices, agrochemicals, insulation products, software, medical imaging and mosquito nets.

Christopher Stothers

Partner, Freshfields Bruckhaus Deringer LLP
Christopher Stothers

Christopher is a recognized expert in parallel trade, with a particular focus on the pharmaceutical sector - his 2007 textbook, “Parallel Trade in Europe: Intellectual Property, Competition and Regulatory Law,” has been cited by the UK Supreme Court. Christopher is also an experienced litigator on cross-border patent disputes, other types of intellectual property, antitrust, pharmaceutical regulation, EU law and commercial disputes. He has taken cases before the First Tier Tribunal, the Upper Tribunal, the Patents County Court, the High Court, the Court of Appeal, the House of Lords, the Supreme Court, the European Patent Office, and the European Court of Justice.

David Guest

Manager, Parallel Import Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
David Guest

After more than 20 years as a Process Development chemist for a major pharmaceutical company, David joined one of the largest UK Parallel Importers as Regulatory Affairs Manager. His 5 year tenure gave him a good understanding of the restrictions and pressures on importers.
Since joining MHRA as Manager of the Parallel Import Unit this industry experience has been beneficial in guiding changes to the internal assessment processes to provide a better service to industry while ensuring an appropriate focus on patient safety.
 

Dermot Glynn

Senior Advisor, Europe Economics
Dermot Glynn

Dermot Glynn is Senior Advisor to and founder of Europe Economics.

His areas of expertise include economic regulation, competition policy, and public policy evaluation. He has worked extensively in the utility sectors, directing consultancy projects and providing expert advice to both regulators and regulated businesses. He has led numerous seminars on regulatory issues and on the concepts and techniques of impact assessment of public policies, and advised the National Audit Office (NAO) in its technical review of impact assessments carried out by UK Government Departments and agencies.

Before founding Europe Economics Dermot Glynn served as Economic Director of the Confederation of British Industry (CBI), Chief Economist at KPMG, and UK Managing Director of NERA. He read Politics, Philosophy and Economics at Balliol College, Oxford, and was a member of the Department of Applied Economics at Cambridge University.

Farasat Bokhari

Associate Professor, UEA, University of East Anglia
Farasat Bokhari

Farasat Bokhari is a Senior Lecturer (Associate Professor) in the School of Economics and Centre for Competition Policy at the University of East Anglia. He is a health economist with a background in applied microeconomics and industrial organization, with a specialization in health policy. He has conducted research related to impact of public health financing on health outcomes as well as of other regulations on healthcare utilization. Dr. Bokhari’s research extends to competition and antitrust in the healthcare sector. His recent work is on welfare effects of new entrants, particularly of generic and follow-on (`me-too') drugs in the pharmaceutical markets. He has been active in studying firm strategies relating to pricing, launch of authorized generics, conducting pay-for-delay deals, and product differentiation and mergers and their impact on industry performance and structure.

 

Jeremy Blum

Partner, Bristows
Jeremy Blum

Jeremy is an IP specialist and has advised on many contentious matters involving trade marks, copyright, designs, patents and confidential information. He has a particular focus on trade marks, design and copyright. He has advised on a number of high profile disputes before the High Court, Court of Appeal, Court of Justice, EUIPO and General Court. He has even led the advocacy before the Court of Justice.
Jeremy has acted in some of the leading cases that have developed intellectual property law such as:
• L’Oreal v eBay which concerned the liability of online e-commerce platforms and was the first case to consider injunctions against non-infringing intermediaries
• Cadbury v Nestle which concerned the registrability of the shape of a four-fingered KitKat chocolate bar
• Glaxo v Sandoz concerning the colour and shape of an asthma inhaler for passing off.
Jeremy also has extensive registered design, unregistered design and copyright litigation experience for a diverse range of products ranging from luxury jewellery and fashion, plastic containers, artworks, pharmaceutical products and consumer goods.
In particular Jeremy is a specialist in advising on strategies to combat IP infringement in the digital world and has advised on a number of cases regarding online infringement. As a consequence, Jeremy also has a particular interest in cross border injunctions and jurisdiction for community trade marks and designs as well as copyright.
As part of his breach of confidential information practice, Jeremy has considerable experience in arbitration and has acted in cases before the LCIA and SCC (Stockholm Chamber of Commerce) as well as ad hoc arbitrations. Jeremy specialises in arbitration involving technical subject matter and his cases have ranged from chemical compounds used in deodorants to chemical processes. Many of his arbitration cases involve substantial damages claims.
Jeremy also provides advice in relation to European regulatory aspects of food and beverage labelling.

 

John Lisman

Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
John Lisman

John Lisman is trained both as a pharmacist and a lawyer. From 1992 until 2007 he was a policy officer in the Ministry of Health and the Medicines Evaluation Board and represented the Netherlands in the Heads of Agencies meeting and the European Medicines Agency Management Board. In 2007 John changed his course to become a private lawyer, first in the largest law firm in the Benelux, NautaDutilh, and since 2010 in Lisman Legal Life sciences B.V..
John Lisman is publishing broadly in journals and has published more than 200 annotations in Dutch case law collections. He has presented many papers in the Netherlands and abroad.
 

Kasper Ernest

Secretary General, European Association of Euro-Pharmaceutical Companies
Kasper Ernest

Kasper Ernest has worked for the last 9 years in European affairs advocacy in Brussels. From 2009 -2018 he was with the Confederation of Danish Enterprise, since 2015 serving as Director of the EU & International Department. He has also served as the Board Member of several EU-level business organisations, as a Member of the Danish Government’s Implementation Council, and was co-founder of the European Business Services Alliance. In addition, he is an external lecturer at Copenhagen Business School. He holds a Master’s degree in International Business and Politics from Copenhagen Business School and Singapore Management University.

Martin Slegl

Regional Principal of East Europe, IQVIA
Martin Slegl

• Martin has over 9 years experience in the area of management consulting, he was leading South East Europe consulting with IQVIA (10 countries). His current role is General Manager for the Czech Republic and Slovakia
• His specialty is cross border trade and he has worked for a large number of HQs across Europe in different therapy areas
• He has proven project experience across a variety of industries through Europe as he worked with Roland Berger and A.T. Kearney
• Martin holds CEMS Master's in International Management and Master’s in Business Economics degrees from ESADE and University of Economics in Prague
 

Mike Isles

Executive Director, European Alliance for Access to Safe Medicines
Mike Isles

Peter Bogaert

Managing Partner, Covington & Burling
Peter Bogaert

Peter Bogaert is a managing partner of the Brussels office, and has a broad European life sciences practice. He has detailed regulatory expertise under EU and national laws, handles legislative and other policy assignments and provides strategic advice. He also represents life sciences companies before the European Courts in Luxembourg and in local litigation in Belgium. Mr. Bogaert's practice covers pharmaceuticals, biotechnology, medical devices, special foods and feed, cosmetics and other consumer products and he represents numerous innovative life sciences companies, including start-ups, as well as several industry associations.
Chambers Global notes that a client said “He is an extremely experienced professional with broad expertise and provides sensible and well-balanced solutions." He is consistently ranked by PLC as one of the leading life sciences lawyers globally and Legal 500 EMEA and Chambers Europe note Mr. Bogaert's prominent regulatory pharmaceutical and environmental practice. Legal 500 EMEA (2011) noted that he is "a superb lawyer who is very pleasant to work with." Mr. Bogaert regularly writes and speaks on life sciences issues. He is a founding member of the Brussels Pharma Law Group.

 

Richard Freudenberg

President - Chief Executive, BAEPD
Richard  Freudenberg

Richard Freudenberg has worked in the PPDI since 1990, for 15 years as Finance Director and subsequently as Managing Director of founder BAEPD member, Doncaster Pharmaceuticals Group Limited.
Richard has also been a BAEPD Director and member of the association's managing Council from December 2001, and acceded to the BAEPD secretariat in 2005. He has during this period also been (since 2011) Chief Executive of, and twice President (2007-2008 & 2011 to date) of EAEPC

 

Sandor Beukers

Senior Policy Manager, Department of Health and Social Care
Sandor Beukers

Sandor is Senior policy manager in the Medicine and Pharmacy Directorate at the Department of Health and Social Care. He has 10 years of policy experience in medicines. His current focus is on pricing of generic medicines, reimbursement of community pharmacy, dispensing efficiencies and implementation of the Health Service Products (Provision and Disclosure of Information) Regulations 2018. He also led on the introduction of the parallel export restrictions.

Shabnam Hanassab

Engagement Manager, IQVIA
Shabnam Hanassab

IQVIA’s expert and thought leader in European Parallel Trade dynamics, supply chain and distribution with several years of experience working in this field. Shabnam has developed in-depth expertise in pharmaceutical market dynamics and the increasing complexities of the trading environment. Shabnam is highly experienced on IQVIA’s data types, coverage and various supply chain offerings available centrally as well as locally, working with network of people within and outside organization. She has led several European supply chain consulting projects in the past few years.
Shabnam holds BSc, MSc and PhD from University of London in Pharmaceutical and Computational Chemistry.
 

Susan Grieve

Principal Pharmacist , Department of Health and Social Care
Susan Grieve

Susan is Principal pharmacist in the Medicine and Pharmacy Directorate at the Department of Health and Social Care. She leads a team of pharmacists and policy professional responsible for a range of policy areas related to generic pricing, reimbursement of community pharmacy, implementation of the Falsified Medicines Directive, pharmacy IT, dispensing efficiencies, clinical service delivery in community pharmacy and supply chain issues. The team’s current work includes the community pharmacy contractual framework 5 year deal announced last summer and the Medicines and Medical Devices Bill. She joined the Department after having gained experience in a Health Authority and community pharmacy before that.

Tushar Patel

Principal Consultant, Key Pharmaceuticals Ltd
Tushar Patel

My core profession is as a community pharmacist. I own and manage two retail pharmacies currently which provides me the critical link between medicines and the patient.
Parallel Imports is where I began my career in regulatory projects for start-up of parallel import companies in the UK. I facilitated application for MHRA Manufacturing Licences ML(Ao) and PL(PI) applications for various clients. Since 2014 my competency and training has been project management, formulation & development of generics, GMDP and Pharmacovigilance. Currently fully engrossed with our fully encompassed pharma company with all regulatory disciplines in house and over 15 EU Marketing Authorisations. I am a EU QPPV and a trainee EU QP.
My ambition has already been fulfilled to develop, manufacture and dispense our own medicines to our own customer in our own pharmacies. Now looking ahead to help others better serve patients locally and globally with safer medicines.

 

Werner Berg

Partner, Baker & Mckenzie
Werner Berg

Dr. Werner Berg, LL.M, is a partner in the Antitrust & Competition Practice Group in Baker McKenzie, Brussels. Werner has extensive experience advising in the life sciences/pharmaceuticals and chemical industries. He advises on all aspects of European and German antitrust law. Werner has represented companies in numerous merger cases, counseled and represented companies in abuse of dominance investigations and has conducted more than 20 litigation matters before the European Union courts. He is ranked as a recommended Lawyer in Chambers Global and Chambers Europe, the EMEA Legal 500, Best Lawyers and European Legal Experts and features as Acritas Star since 2018.
He has written more than 100 articles and contributions to commentaries on competition and EU law, and is the co-editor of Berg/Mäsch, Deutsches und Europäisches Kartellrecht 3rd ed. 2018. Werner teaches competition law at Queen Mary College, University of London, the College of Europe and the University of Trier.
 

Wesley Lepla

Regulatory Lawyer, Covington & Burling
Wesley Lepla

Wesley Lepla advises on all aspects of Belgian and European competition law, including merger control, cartels, anticompetitive agreements, abuse of a dominant position, and state aid law.
He has worked on a range of merger control cases before the European Commission and numerous national authorities and has gained extensive experience in coordinating multijurisdictional merger control notifications and proceedings. Mr. Lepla has represented clients in antitrust proceedings and regularly counsels on state aid, vertical agreements, and the licensing of intellectual property rights.
Mr. Lepla is also a research and teaching assistant at the law faculty of the Free University of Brussels (VUB).
 

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Introductions

Tushar Patel

Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

clock

9:10

The background to PT from conception to trading models and the current consequences and challenges of PT

Tushar Patel

Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

clock

9:50

Understanding and discussing where are we now in terms of Brexit strategies for implementation and where do we go from here?

Tushar Patel

Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

clock

10:30

Morning Coffee

clock

11:00

The future of Parallel Trade, what opportunities and threats should be considered in line with realistic expectations?

Tushar Patel

Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

clock

11:40

Recap & Q&A

Tushar Patel

Tushar Patel, Principal Consultant, Key Pharmaceuticals Ltd

clock

12:30

Closing Remarks and End of Workshop

clock

13:30

Registration & Coffee

clock

14:10

Case study 1: Competition law and management strategies

•Legal principles - Articles 101/102 TFEU and case law
•Quota systems and potential risks
•Agency (direct to pharmacy/hospital) systems and potential risks
•Other competition risks and red flags
 

John Schmidt

John Schmidt, Partner, Arnold and Porter

Beatriz San Martin

Beatriz San Martin, Partner, Arnold & Porter

clock

14:50

Case study 2: Trade mark exhaustion and repackaging

•Legal principles - trade mark exhaustion
•BMS conditions - when and how can goods be repackaged?
•Consent to sale of goods in the EEA - what about related and group companies?
 

John Schmidt

John Schmidt, Partner, Arnold and Porter

Beatriz San Martin

Beatriz San Martin, Partner, Arnold & Porter

clock

15:20

Afternoon Tea

clock

15:50

Case Study 3: SPC Waiver and Brexit Implications

 • SPC Waiver - how does it work?
• Brexit implications - what happens to SPC Waiver in a “no deal” situation?
 

John Schmidt

John Schmidt, Partner, Arnold and Porter

Beatriz San Martin

Beatriz San Martin, Partner, Arnold & Porter

clock

17:30

Closing Remarks and End of Workshop

John Schmidt

John Schmidt, Partner, Arnold and Porter

Beatriz San Martin

Beatriz San Martin, Partner, Arnold & Porter

clock

8:30

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies

clock

9:10

The political economy of parallel trade

Dermot Glynn, Senior Advisor, Europe Economics

  • The law of one price
  • The Justification for patents
  • Efficient pricing for patented products
  • Alternative objectives of competition law
  • Consumer welfare
  • EU integration
  • Squaring the circle
  • Brexit
  •  

    clock

    9:50

    Regulatory update and overview: Where are we now with Parallel Trade?

    • Reviewing the underlying regulatory structure on parallel trade and how regulation must be recognised and placed on the market in the EU
    • Understanding the relevance of this and depending on the country of focus, what pressures there are on exports of products
    • Gaining clear understanding and interpretation of competition law and how these interactions are made with IP Ascertaining what changes Brexit will have on the ability of manufactures to manage PT
     

    Peter Bogaert, Managing Partner, Covington & Burling

    Wesley Lepla, Regulatory Lawyer, Covington & Burling

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Competition Law - An update

    Werner Berg, Partner, Baker & Mckenzie

    • Parallel trade – key issues and EU law
    • Enforcement overview: European Commission and National Authorities
    • Practical options for pharmaceutical companies
    • Outlook

     

    clock

    11:40

    Parallel trade and availability of medicines

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.

  • Analysis of the causes of medicine shortages
  • Regulatory activity in solving the problem of shortages
  • Role of parallel trade in causing and solving shortages


  •  

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Exploring and understanding exhaustion of IP rights

    Beatriz San Martin, Partner, Arnold & Porter

    • When are patent and trade mark rights exhausted in the EEA and how?
    • Potential areas for disputes: parallel import, repair and modification, and repackaging of products
    • Implications of Brexit
     

    clock

    14:00

    Insight into latest trends of Parallel Trade across EU and main drivers

    Shabnam Hanassab, Engagement Manager, IQVIA

    • Overview on PI sales trends across EU in 2019 compared to past
    • Glance on latest main drivers of PI sales, Brexit and German new legislations
    • Updates on other drivers
     

    clock

    14:40

    PANEL DISCUSSION

    • Underlying principles of the EU Internal market and Competition policies
    • What lies behind the EU fundamental thinking of institutions as drivers for trade, competition and the EU market?
    • What is the policy, legal and motivational drivers?
     

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.

    Werner Berg, Partner, Baker & Mckenzie

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies

    Aqeel Kadri, Senior Associate , White & Case LLP

    clock

    15:20

    Chair’s Closing Remarks and Close of Day One

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies

    clock

    15:30

    Afternoon Tea

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies

    clock

    9:10

    Assessing the current situation, impact and consequences of Parallel Trade?

    David Guest, Manager, Parallel Import Unit, Medicines & Healthcare products Regulatory Agency (MHRA)

    • Where are we now with Parallel Trade?
    • Evaluating whether there would be an increase in medicine prices, reduced access to some drugs and an increased risk of supply chain shortages
    • Understanding the challenges that could lie ahead regarding medicines importation

    clock

    9:50

    Medicines shortages and parallel trade

  • The Department’s approach to medicines shortages
  • Parallel trade and medicines shortages
  • Parallel export restrictions

  •  

    Susan Grieve, Principal Pharmacist , Department of Health and Social Care

    Sandor Beukers, Senior Policy Manager, Department of Health and Social Care

    clock

    10:30

    Morning Coffee

    clock

    11:00

    DEEP DIVE SHORTAGES PANEL DISCUSSION: The impact on patient safety

    • How does Parallel Trade (PT) management help ensure patient safety?
    • Does PT help ensure a continuous supply chain to patients in the UK?
    • What principles or measures are in place to help ensure that PT does not encourage medicine shortages especially in Member States that have significantly lower prices?
    • What hurdles does Competition law bring to PT?
    • Are there any ways to change the market dynamic and therefore the business model to reduce the level of shortages?
    • How might product shortages effect consumer/patient behaviour?
    • What impact might the Internet have on future buying patterns for medicines?

     

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.

    Richard Freudenberg, President - Chief Executive, BAEPD

    Susan Grieve, Principal Pharmacist , Department of Health and Social Care

    Mike Isles

    Mike Isles, Executive Director, European Alliance for Access to Safe Medicines

    clock

    11:40

    Open Discussion

    Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP

    This session will be chaired by Christopher, who will set the scene before breaking out into group discussion on the key topics below, with twenty minutes per bullet point to allow some fruitful and open discussions amongst the groups:
    • What are the significant medium- and long-term impact for UK intellectual property rights and exhaustion?
    • Will the transitional regime(s) provide continuity in the UK and in the EU?
    • How may UK IP law diverge from the EU over time?
     

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Product Proliferation: Entry deterrence, market shares and growth

    Farasat Bokhari, Associate Professor, UEA, University of East Anglia

    This talk will focus on strategic and non-strategic reasons for introducing additional drugs by a monopolist near the end of market exclusivity period for the original drug.
    • Are these drugs introduced to deter generic entry, and if so, is it an effective strategy?
    • Similarly, post entry, do additional product and pack variations by an incumbent help with revenue growth of the business unit?
    • Questions will be analysed using sales and entry data from the UK market
     

    clock

    14:00

    Out of Industry Case Study: Mitsubishi

    Jeremy Blum, Partner, Bristows

    • Infringing and interfering with trademarks
    • The implications of entire removal of brand from the product
    • The challenges, hurdles and implications in the Mitsubishi case study and how this can be applied to pharma
     

    clock

    14:40

    Insights into Eastern Europe (EE)

    Martin Slegl, Regional Principal of East Europe, IQVIA

    • Updates about distribution legal changes across EE
    • Availability of specialty drugs in EE
    • EE as import market(s)
     

    clock

    15:20

    Chair’s Closing Remarks and Close of Day Two

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies

    clock

    15:30

    Afternoon Tea


    Senior Associate
    White & Case LLP
    Partner
    Arnold & Porter
    Partner
    Freshfields Bruckhaus Deringer LLP
    Manager, Parallel Import Unit
    Medicines & Healthcare products Regulatory Agency (MHRA)
    Senior Advisor
    Europe Economics
    Associate Professor
    UEA, University of East Anglia
    Partner
    Bristows
    Attorney, Consultant, Trainer
    Lisman Legal Life sciences B.V.
    Secretary General
    European Association of Euro-Pharmaceutical Companies
    Regional Principal of East Europe
    IQVIA
    Executive Director
    European Alliance for Access to Safe Medicines
    Managing Partner
    Covington & Burling
    President - Chief Executive
    BAEPD
    Senior Policy Manager
    Department of Health and Social Care
    Engagement Manager
    IQVIA
    Principal Pharmacist
    Department of Health and Social Care
    Principal Consultant
    Key Pharmaceuticals Ltd
    Partner
    Baker & Mckenzie
    Regulatory Lawyer
    Covington & Burling

    Workshops

    Parallel Trade Infographic

    Download

    Speaker Interview with Martin Slegl

    Download

    Speaker Bio's for 2020

    Download

    Speaker Interview - John Lisman, Lisman Legal Life sciences B.V.

    Download

    Full Programme

    Download

    Parallel Trade brochure 2020

    Download

    Past Attendees 2018-2019

    Download

    PAST PRESENTATION BY VENEZA YUZON, AMGEN

    Download

    PAST PRESENTATION BY PAUL UPHAM, ROCHE

    Download

    PAST PRESENTATION BY MICHAEL SONG, MEDIMMUNE

    Download

    PAST PRESENTATION BY LARRY ATUPEM, ZEON

    Download

    PAST PRESENTATION BY JOKE MAES, TERUMO, CHRIS FRANZESE AND MOLLY LARSON-WAKEMAN, MATCHSTICK

    Download

    PAST PRESENTATION BY ED ISRAELSKI, CHPF

    Download

    PAST PRESENTATION BY DAVID POST, ABBVIE

    Download

    PAST PRESENTATION BY SHOTA ARAKAWA, MITSUBISHI GAS CHEMICAL

    Download

    PAST PRESENTATION BY URI BARUCH, CAMBRIDGE DESIGN PARTNERSHIP

    Download

    PAST PRESENTATION BY PIERRE GOLDBACH, ROCHE

    Download

    PAST PRESENTATION BY MICHAEL HOOVEN, ENABLE INJECTIONS

    Download

    PAST PRESENTATION BY JOEL RICHARD, IPSEN

    Download

    PAST PRESENTATION BY JAYNE LAWRENCE, THE UNIVERSITY OF MANCHESTER

    Download

    PAST PRESENTATION BY FRANCESCO MALAVASI, NOVARTIS

    Download

    PAST PRESENTATION BY FIE FALCK LARSEN, LEO

    Download

    PAST PRESENTATION BY DR. ANDREW FIORINI, GSK

    Download

    PAST PRESENTATION BY DR. AHMED YOUSSEF, SANOFI

    Download

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.